Status:
COMPLETED
VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Excessive Somnolence
Eligibility:
All Genders
18-40 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and efficacy of VSF-173 compared to placebo in treatment of induced excessive sleepiness.
Eligibility Criteria
Inclusion
- Healthy subjects with no medical, psychiatric, or current sleep disorders
- Subject must sign a written consent form
Exclusion
- Evidence of excessive daytime sleepiness
- History of sleep disorders
- Psychiatric or neurological disorders
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00467441
Last Update
November 2 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Dijon, France